MedTrace Logo

Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis

NCT04749667 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-03-12

No results posted yet for this study

Summary

The primary objective of the study is to investigate neuroregenerative efficacy (proof of concept) of intrathecal treatment with autologous MSCs as measured by neurophysiological parameters in patients with progressive MS.

Secondary objectives are to assess neuroregenerative efficacy as measured by other neurophysiological parameters as well as clinical, opthalmological and MRI modalities, and to assess safety of the treatment procedure.

Conditions

Interventions

OTHER

MSCs

Autologous bone-marrow derived mesenchymal stem cells

DRUG

Saline

Isotonic saline

Sponsors & Collaborators

  • University of Bergen

    collaborator OTHER

  • University Hospital Ulm

    collaborator OTHER

  • University Hospital, Akershus

    collaborator OTHER

  • University Hospital of North Norway

    collaborator OTHER

  • St. Olavs Hospital

    collaborator OTHER

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Christopher Elnan Kvistad, PhD · Haukeland University Hospital

  • Lars Bø, Prof · Haukeland University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-09
Primary Completion
2025-03-24
Completion
2027-03-15

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04749667 on ClinicalTrials.gov